Adcetris (brentuximab vedotin)

pCPA File Number: 22856

Negotiation Status:

Under consideration for negotiation

Indication(s):

High-risk Hodgkins Lymphoma in the pediatric population, previously untreated (in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide); Advanced stage Hodgkins Lymphoma, previously untreated (in combination with doxorubicin, vinblastine, and dacarbazine)

Sponsor/Manufacturer:

Seattle Genetics Inc.

CDA-AMC Project Number:

PC0371-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable